← Back to Clinical Trials
Recruiting NCT06881069

NCT06881069 Reach Through Equitable Implementation in Utah

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06881069
Status Recruiting
Phase
Sponsor University of Utah
Condition Tobacco Use Cessation
Study Type INTERVENTIONAL
Enrollment 1,560 participants
Start Date 2025-02-13
Primary Completion 2027-11-15

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Clinic Level: AAC - SDOH, AAC - TobaccoNon-BundledBundled

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 1,560 participants in total. It began in 2025-02-13 with a primary completion date of 2027-11-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this pragmatic, multilevel Type III Hybrid Effectiveness-Implementation trial is to increase the reach of existing evidence-based interventions (EBIs) for tobacco cessation and to mitigate the impact of adverse Social Drivers of Health (SDOH) among safety-net healthcare system patients who live in persistent poverty (PP) census tracts. Aim 1: Test the ability of patient-level Conversational Agents (CA) \& Patient Navigation (PN) dissemination strategies to increase the Reach (primary outcome) of evidence-based tobacco cessation treatment delivered via the Utah Tobacco and Nicotine Quit Services (Quit Services) among Community Health Center (CHC) patients who use tobacco and live in persistent poverty census tracts. Secondary analyses will examine the outcome of Reach of services for SDOH among these patients and will evaluate both 1) patient-level CA and PN dissemination strategies and 2) a clinic-level implementation strategy using a pre-post design. Aim 2: Explore contextual factors (e.g., clinic size, patient composition, rurality, patient demographics) related to the Reach, Adoption, Implementation, and potential Maintenance of strategies. Aim 3: Determine the cost-effectiveness of clinic and patient-level strategies based on Quit Services enrollment and service receipt for SDOH. This trial implements a clinic-level implementation strategy, Ask-Advise-Connect (AAC), to address tobacco cessation and needs around social drivers of health for patients in all participating clinics. Eligible patients who are not enrolled in Quit Services four weeks after the clinical encounter, will receive text messages from a chatbot offering information and connections to the Quit Services and patient navigation support from a Community Health Worker.

Eligibility Criteria

Inclusion Criteria: * ≥ 18 years of age * Speak English or Spanish * Currently use tobacco * Live in a persistent poverty census tract * Present at participating clinics * Valid cell phone number in the electronic health record (EHR) * Electronic health records indicate they have not opted out of receiving text contact from the clinic Exclusion Criteria: * Opt-out of study

Contact & Investigator

Central Contact

Chelsey Schlechter, PhD

✉ chelsey.schlechter@hci.utah.edu

📞 801-213-5704

Principal Investigator

Chelsey Schlechter, MPH, PhD

PRINCIPAL INVESTIGATOR

Huntsman Cancer Institute/ University of Utah

Frequently Asked Questions

Who can join the NCT06881069 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Tobacco Use Cessation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06881069 currently recruiting?

Yes, NCT06881069 is actively recruiting participants. Contact the research team at chelsey.schlechter@hci.utah.edu for enrollment information.

Where is the NCT06881069 trial being conducted?

This trial is being conducted at Salt Lake City, United States.

Who is sponsoring the NCT06881069 clinical trial?

NCT06881069 is sponsored by University of Utah. The principal investigator is Chelsey Schlechter, MPH, PhD at Huntsman Cancer Institute/ University of Utah. The trial plans to enroll 1,560 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology